-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Haemanthamine
Category | Influenza Virus |
CAS | 466-75-1 |
Description | Haemanthamine is a crinine-type alkaloid isolated from the Amaryllidaceae plants with anticancer, pro-apoptotic, antioxidant, antiviral, antimalarial and anticonvulsant activities. It targets ribosomal that inhibits protein biosynthesis during the translational elongation phase. |
Product Information
Synonyms | (+)-Haemanthamine; Natalensin; 3-Epicrinamine; NSC403140; Natalensine; Haemanthamin; Hemanthamine; (3β,11R,13β,19α)-3-Methoxy-1,2-didehydrocrinan-11-ol; 3H,6H-5,11b-Ethano[1,3]dioxolo[4,5-j]phenanthridin-12-ol, 4,4a-dihydro-3-methoxy-, (3S,4aS,11bS,12R)-; (3β,5α,11R,13β,19α)-1,2-Didehydro-3-methoxycrinan-11-ol |
IUPAC Name | (1S,13S,15S,18R)-15-methoxy-5,7-dioxa-12-azapentacyclo[10.5.2.01,13.02,10.04,8]nonadeca-2,4(8),9,16-tetraen-18-ol |
Molecular Weight | 301.34 |
Molecular Formula | C17H19NO4 |
Canonical SMILES | COC1CC2C3(C=C1)C(CN2CC4=CC5=C(C=C34)OCO5)O |
InChI | InChI=1S/C17H19NO4/c1-20-11-2-3-17-12-6-14-13(21-9-22-14)4-10(12)7-18(8-16(17)19)15(17)5-11/h2-4,6,11,15-16,19H,5,7-9H2,1H3/t11-,15+,16+,17+/m1/s1 |
InChIKey | YGPRSGKVLATIHT-HSHDSVGOSA-N |
Boiling Point | 467.5±45.0°C at 760 mmHg |
Flash Point | 236.5°C |
Purity | ≥95% |
Density | 1.4±0.1 g/cm3 |
Solubility | In Vitro: DMSO : 100 mg/mL(331.85 mM;Need ultrasonic) |
Appearance | White to off-white (Solid) |
Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
Complexity | 497 |
Exact Mass | 301.13140809 |
Index Of Refraction | 1.679 |
In Vitro | Haemanthamine (1-100 µM; 24-48 hours; A2780 cells) treatment shows a time- and dose-dependent decrease in cell viability. Haemanthamine (10 µM; 24-72 hours; A2780 cells) treatment leads to a significant inhibition of A2780 cell proliferation. Haemanthamine binds at the A-site cleft of the peptidyl transferase center on the large ribosomal subunit, creating unique molecular interactions with the 25S rRNA. Haemanthamine has a highly specific inhibitory effect on pre-rRNA processing, leading to the activation of a p53-dependent antitumoral surveillance pathway known as nucleolar stress. |
In Vivo | A pharmacokinetic study of Haemanthamine in rats shows a rapid distribution phase of 30 min, a half-life of 70.4 min, and a major clearance through renal elimination. The high distribution volume of 13.7 L/kg suggests a high intracellular penetration, and its plasmatic concentration remains higher than 1 μM for at least 1 hr after a single 10-mg/kg administration. |
PSA | 51.16000 |
Target | Apoptosis; Influenza Virus; Parasite |
Vapor Pressure | 1.53E-09mmHg at 25°C |
XLogP3-AA | 1.3 |